Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Farabi Pharmaceutical's Net-Net Working Capital for the quarter that ended in . 20 was IRR0.00.
The industry rank for Farabi Pharmaceutical's Net-Net Working Capital or its related term are showing as below:
XTEH:DFRB1's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.75 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Farabi Pharmaceutical (XTEH:DFRB1) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Farabi Pharmaceutical Net-Net Working Capital Related Terms
Farabi Pharmaceutical Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Farabi Pharmaceutical's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Farabi Pharmaceutical Net-Net Working Capital Chart
Farabi Pharmaceutical Annual Data
Trend
Net-Net Working Capital
Farabi Pharmaceutical Quarterly Data
Net-Net Working Capital
XTEH:DFRB1 vs IMNPQ, INNV: Net-Net Working Capital Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Farabi Pharmaceutical's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Farabi Pharmaceutical Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Farabi Pharmaceutical's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Farabi Pharmaceutical's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of IRR0.00 mean?
Farabi Pharmaceutical (XTEH:DFRB1) has a Net-Net Working Capital of IRR0.00 as of . 20. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Farabi Pharmaceutical
Is Farabi Pharmaceutical's Net-Net Working Capital too high?
Farabi Pharmaceutical's current Net-Net Working Capital is IRR0.00.
How does Farabi Pharmaceutical's Net-Net Working Capital compare to IMNPQ and INNV?
Farabi Pharmaceutical's Net-Net Working Capital of IRR0.00 can be compared against companies in the Drug Manufacturers industry. The industry median Net-Net Working Capital is 7.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 7.75, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Farabi Pharmaceutical For the Drug Manufacturers industry, the median Net-Net Working Capital is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Farabi Pharmaceutical's current Net-Net Working Capital is IRR0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Farabi Pharmaceutical stock overvalued right now?
Farabi Pharmaceutical (XTEH:DFRB1) has a current Net-Net Working Capital of IRR0.00. The current Net-Net Working Capital is IRR0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Farabi Pharmaceutical (XTEH:DFRB1), the current Net-Net Working Capital is IRR0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Farabi Pharmaceutical is a pharmaceutical company based in Iran. It produces various oral antibiotic-related and non-antibiotic products and dietary supplements. The company develops anti-migraine, antivirals, cholesterol, diabetic, cardiovascular, gastrointestinal, neuroleptics, anti-prostatic and anti-inflammatory and pain release drugs. It offers products in the form of tablet, capsule and suspensions which include Amoxicillin, Cefixime, Azithromycin, Ciprofloxacin, Nitroglycerin, Repaglinide, Orlistat, Domperidone, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTEH:DFRB1 has been successfully added to your 
